Vimta Labs Ltd Q2 FY26 Earnings Analysis

Published 1 Jun 2026 | Market Cap: ₹2.9K Cr

Price

₹616

Market Cap

₹2.9K Cr

P/E Ratio

36.3

Earnings Summary

Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors. Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY.

📊 Revenue & Sales Performance

→Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors.
→All verticals—pharma, food, electronics—are anticipated to grow at similar rates (7.5% to 9%), with pharma dominating revenue share (~65%) and food contributing ~20%.
→Biologics and large molecule formulation development services are emerging growth areas, with commercialization expected by Q1 FY 2027.
→Expansion in capacity across all verticals (pharma, food, electronics, preclinical, GMP testing) has been done to support growth without immediate capacity constraints.
→Increasing client demand for biologics development and outsourcing trends will further boost pharma segment growth.
→International markets offer opportunities for new business and market share gain, particularly in pharma.
→Electronics and environment testing show stable to moderate growth but contribute smaller revenue shares.
→Overall, the company targets maintaining and improving the INR100 crore quarterly revenue run-rate, supported by ongoing capex and expanding client base.

📈 Profitability & Margins

→Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY.
→PAT for H1 FY '26 grew 25.5% YoY at INR 388 million with PAT margin at 19%.
→Management expects continued growth primarily from pharmaceutical research/testing and food testing services.
→New biologics formulation development services to commercialize by Q1 FY '27, expected to contribute to growth.
→No immediate capacity constraints due to recent infrastructure expansions; incremental revenues expected as resources and equipment scale up.
→Margins are stable across verticals, with environment testing margins slightly lower.
→Capex of ~INR 25 crores planned for biologics over 2 years to support lifecycle integration and new service lines.
→Overall, the company anticipates sustained earnings growth driven by expanding capacities and new service offerings in biopharma.

🏗️ Capital Expenditure Plans

→Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan.
→Biologics segment capex is around INR25 crores for this year, with a similar amount planned for the next year ('27).
→Capex is spread across pharmaceuticals, food, and electrical & electronic testing verticals.
→Investments focus on expanding capacities, including new equipment and infrastructure.
→Some capex backed by visibility from client pipelines; others are inherent to newly created capacities.
→Clinical research requires minimal capex as studies in patient populations are off-site.
→The biologics segment expansion includes backward integration from preclinical to formulation development.
→Phase 1 of the new facility is largely utilized, with Phase 2 currently about 50-60% utilized and expected to support future growth.

💰 Fundraising & Capital Structure

→There is no specific mention of any current or planned fundraising through debt or equity in the provided document.
→The company maintains a net debt-free balance sheet with cash and cash equivalents of INR 545 million, indicating a strong cash position.
→Capex plans for FY '26 and '27 around INR 25 crores annually are funded internally, primarily for biologics and capacity expansion across verticals.
→Expansion and growth plans appear to be backed by internal accruals and existing resources rather than external fundraising.
→The management did not indicate any immediate need for raising external funds during the call.

📋 Order Book & Pipeline

→The company did not provide explicit current orderbook or pending order values during the call.
→They mentioned having strong order pipelines, especially in the pharmaceutical segment, mainly supporting generic product development.
→Preclinical business supports both discovery (35%) and generic, specialty chemicals, regulatory work (65%).
→The clinical trial business pipeline is growing, with intensified business development operations.
→The newly added CMO/CRADS vertical is part of the expansion backed by visibility of pipelines and client interest.
→Expansion into biologics and formulation development is driven by growing demand and client requests.
→The company bases some capex on visible pipelines, indicating confidence in upcoming orders.
→Defence segment has continuous work with expanding clientele, implying ongoing order flow.

Key Metrics

Frequently Asked Questions

What were Vimta Labs Ltd Q2 FY26 results?

What is Vimta Labs Ltd share price analysis?

Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 36.3 with a market cap of ₹2,935 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vimta Labs Ltd planning capital expenditure?

Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.